Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025

Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

19,347,033

Number of real voting rights* (excluding treasury shares**)

19,280,095

Theoretical number of voting rights* (including treasury shares**)

19,323,833

(*) Class E preference shares are non-voting

(**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610017701/en/

The Median Technologies Stock at the time of publication of the news with a fall of -0,48 % to 2,093EUR on Lang & Schwarz stock exchange (10. Juni 2025, 17:49 Uhr).